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Purpose: The objective of these studies was to
evaluate the pharmacokinetic proﬁle, safety, and
tolerability of mirabegron, a β3-adrenoceptor agonist
for the treatment of overactive bladder, including food
effects (low- or high-fat meals) and sex, in healthy
East Asian subjects.
Methods: In total, 5 pharmacokinetic studies of
mirabegron were conducted in healthy East Asian
subjects. Food effects were assessed in 3 randomized,
single-dose studies in young Japanese male subjects
(study 1), male and female subjects (study 2), and
young Taiwanese male and female subjects (study 3).
In the other 2 single- and multiple-dose studies in
young Chinese male and female subjects (study 4 and
study 5), mirabegron was administered as a single
dose under fasted conditions. After the washout
period, mirabegron was administered once daily under
fed conditions for 8 days. Pharmacokinetic parameters
were determined using noncompartmental methods.
Safety and tolerability assessments included physical
examinations, vital signs, 12-lead ECG, clinical labo-
ratory tests (biochemistry, hematology, and urinaly-
sis), and adverse event monitoring.
Findings: After administration of single oral doses
of mirabegron, exposure under fed conditions was
lower than under fasted conditions in Japanese and
Taiwanese subjects. In Japanese subjects, a greater
reduction in mirabegron Cmax and AUC0–1 was
observed after a low-fat meal compared with a high-
fat meal. In Chinese subjects, Cmax was reached at
approximately 4.0 hours after single oral doses.
Mirabegron accumulated 2- to 3-fold on once-daily
dosing of multiple-dose relative to single-dose data.
Steady state was reached within 7 days. AfterMay 2015administration of mirabegron, mean values for Cmax
and AUC in female subjects were higher than those in
male subjects. Mirabegron was well tolerated in
Japanese, Taiwanese, and Chinese subjects.
Implications: Our studies conﬁrm the higher expo-
sure levels of mirabegron in female compared with male
East Asian subjects as found earlier in Western subjects.
Furthermore, the effects of food on the pharmacokinetic
proﬁles appeared to be similar among the 3 populations
tested in our studies. The ﬁndings suggest that there are
no signiﬁcant pharmacokinetic differences among the
Japanese, Taiwanese, and Chinese populations. (Clin
Ther. 2015;37:1031–1044) & 2015 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
Key words: East Asia, healthy volunteers, mirabegron,
pharmacokinetics, Ethnic difference.INTRODUCTION
Mirabegron is a β3-adrenoceptor (AR) agonist discov-
ered by Astellas Pharma Inc in Japan.1 The β3-AR
plays a role in the relaxation of the urinary bladder
detrusor smooth muscle.2 Mirabegron relaxes the
detrusor smooth muscle during the storage phase of
the urinary bladder ﬁll-void cycle by activation of
β3-AR, which increases bladder capacity.1,3
The pharmacokinetic proﬁle of mirabegron after
single and multiple oral doses has been reported in
cohorts of Western, primarily white,4,5 and Japanese61031
Clinical Therapeuticshealthy adult subjects. Mirabegron had a greater than
dose-proportional increase in mirabegron Cmax and
AUC after single and multiple oral doses, which was
due to an increase in absolute bioavailability with
increasing dose.4,5 Mirabegron was cleared by multi-
ple mechanisms (renal and possibly biliary excretion
of unchanged drug and metabolism by multiple
enzymes), with no single predominating clearance
pathway.7 It has been reported that mirabegron oral
controlled absorption system (OCAS) tablets
exhibited a decrease in mirabegron plasma exposure
with food in healthy Western subjects.8 In addition,
weight is an important consideration when comparing
different ethnic populations because weight affects
mirabegron pharmacokinetic parameters.5,6
We conducted 3 food effect studies using single doses
of 50 mg in Japanese male subjects (study 1), 50 and
100 mg mirabegron in healthy Japanese male and
female subjects (study 2), and 50 mg mirabegron in
healthy Taiwanese male and female subjects (study 3).
In addition, we conducted 2 studies using single doses
of 25 mg mirabegron (study 4) or 50 mg mirabegron
(study 5) in healthy Chinese male and female subjects to
evaluate the pharmacokinetic parameters, safety proﬁle,
and tolerability of mirabegron after single and multiple
oral doses. The main purpose of these studies is to
compare the pharmacokinetic parameters of mirabe-
gron in East Asian subjects (Japanese, Taiwanese, and
Chinese). In addition, the pharmacokinetic parameters
of mirabegron in healthy East Asian subjects in these
studies were subsequently compared with those previ-
ously reported for Western healthy subjects.4,5,8
PATIENTS AND METHODS
These studies were conducted in accordance with the
ethical principles based on the Declaration of Helsinki9
and Good Clinical Practice,10 as deﬁned by the
Ministerial Ordinance concerning the standards for the
implementation of clinical studies on pharmaceutical
products, and the regulations stipulated in the Japanese,
Taiwanese, and Chinese Pharmaceutical Affairs Law.
These studies were conducted at single centers and
approved by institutional review boards. Studies 1, 2,
and 4 were conducted in Japan, study 3 in Taiwan, and
study 5 in China.
Subjects
Subjects were eligible for inclusion in the studies if
they met the following criteria: study 1, male Japanese1032subjects aged 20 through 44 years with a weight of
50.0 to o80.0 kg and a body mass index (BMI) of
17.6 to o26.4 kg/m2; study 2, male and female
Japanese subjects aged 20 through 54 years with a
weight of 50.0 to o80.0 kg for male and 40.0 to
o70.0 kg for female subjects and a BMI of 17.6 to
o26.4 kg/m2; study 3, male and female Taiwanese
subjects aged 20 through 45 years, with a weight of at
least 50 kg in male and 45 kg in female subjects and a
BMI of 18.5 through 26.9 kg/m2; study 4, male and
female Chinese subjects aged 20 through 44 years with a
weight of 50.0 to o80.0 kg for male and 40.0 to
o70.0 kg for female subjects and a BMI of 17.6 to
o26.4 kg/m2; and study 5, male and female Chinese
subjects aged 18 through 40 years with a weight of at least
50 kg and a BMI of 19 through 24 kg/m2. All subjects
provided written informed consent before screening.
Study Designs
Study 1 was a phase 1, randomized, open-label,
single oral dose, 2-period, 2-sequence crossover study
to evaluate the effect of food on the pharmacokinetic
parameters of mirabegron in 24 Japanese male sub-
jects. In each treatment period, 50 mg mirabegron was
orally administered to subjects under fasting or fed
(high-fat breakfast) conditions. The washout period
between treatment periods 1 and 2 was 12 days or
longer. The high-fat breakfast was Z900 kcal, and fat
comprised 35% of the total caloric content.
Study 2 was a phase 1, randomized, open-label,
single oral dose, 3-period, 6-sequence crossover study
to assess the effect of food on the pharmacokinetic
parameters of mirabegron (50 or 100 mg) in 72
Japanese subjects (36 each for 50 and 100 mg). Under
fed conditions, subjects received either low-fat meal
(approximately 450 kcal) or a high-fat meal (960 kcal)
at 30 minutes before receiving mirabegron. Each
subject participated in 3 treatment periods, with
washout periods of at least 12 days between periods
1 and 2 and between periods 2 and 3.
Study 3 was conducted as an open-label, random-
ized, crossover study to assess the effect of food on the
pharmacokinetic parameters of single oral doses of
mirabegron (50 mg) administered under fasted and
fed conditions (low-fat breakfast of approximately
450 kcal) in 12 Taiwanese subjects (6 males and 6
females). Each subject participated in 2 treatment
periods separated by a washout period of at least
8 days.Volume 37 Number 5
H. Iitsuka et al.The design of studies 4 and 5 allowed assessment of
mirabegron pharmacokinetic parameters after single
oral dose administration under fasting conditions and
multiple oral dose administration under fed condi-
tions. Both studies enrolled 24 young, healthy, adult,
male and female, Chinese subjects. A single oral dose
of 25 mg (study 4) or 50 mg (study 5) mirabegron was
administered under fasting conditions on day 1 of
both studies. This was followed by a washout period
of 9 days in study 4 and a washout period of 14 days
in study 5. A low-fat meal (approximately 450 kcal)
was served before each administration of study drug
in the multiple dose administration period, which
started on day 10 in study 4 and day 15 of study 5
and lasted for 8 days.
Method of Assigning Subjects to Treatment
Groups
A person responsible for treatment assignment
randomly assigned each subject to treatment sequen-
ces in studies 1, 2, and 3. For studies 4 and 5, no
assignment or allocation was used in this study.
Sample Collection and Analysis
In all studies, blood samples for plasma mirabegron
concentrations were collected into tubes that con-
tained sodium-heparin as the anticoagulant and so-
dium ﬂuoride as the stabilizer. In studies 1, 2, and 3,
blood samples were collected before dosing and at 0.5,
1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, and 72 hours
after dosing in each period. An additional sample was
collected 7 and 96 hours after dosing in studies 2 and
3. In study 2, urine samples for measurement of
unchanged mirabegron were collected no more than
12 hours before dosing and from 0 to 12 hours, 12 to
24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to
96 hours after dosing. In studies 4 and 5, blood
samples were collected before dosing and at 0.5, 1, 2,
3, 4, 5, 6, 7, 8, 12, 16, 24, 36, 48, 72, and 96 hours
after dosing in the single-dose period and on the ﬁnal
day in the multiple-dose period, before the ﬁrst
administration of study drug in the multiple-dose
period, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24
hours after dosing on the ﬁrst day in the multiple-dose
period, and before dosing on days 5, 6, and 7 in the
multiple-dose period. Plasma was collected by centri-
fugation, and plasma and urine samples were stored at
–651C or below until analysis. Liquid-liquid extrac-
tion was used to extract mirabegron from plasmaMay 2015constituents. Urine samples were diluted before anal-
ysis. Samples were assayed by validated liquid chro-
matography analytical methods coupled with LC-MS/
MS using an atmospheric pressure chemical ionization
interface, as described previously with minor modiﬁca-
tions.11 The calibration ranges were 0.20 to 100 ng/mL
in plasma and 10.0 to 5000 ng/mL in urine. In the
bioanalytical method validation studies, within-run
precision (%CV) of quality control standards was
o6.6% for plasma and o8.4% for urine. The
within-run accuracy (relative error) of the assays over
the quality control range ranged from 5.0% to 9.7%
for plasma and 4.0% to 11.0% for urine.
Pharmacokinetic Analysis
The concentration of mirabegron in plasma or
urine was analyzed by noncompartmental methods
using WinNonlin Professional software, version 5.2.1
(studies 1 and 2) or a higher version (Pharsight
Corporation, Mountain View, California). The fol-
lowing pharmacokinetic parameters were obtained as
applicable and as appropriate for each study: Cmax,
Tmax, AUC0–24 and AUC0–1 after single dose admin-
istration, AUC0–τ, t½, CL/F, cumulative percentage of
unchanged drug excreted into the urine up to 96 hours
after dosing, and renal clearance. Actual sampling
times were used in all calculations that involved
sampling times, and nominal sampling times were
used for the mean concentration-time ﬁgures.
Safety and Tolerability Assessments
Tolerability was assessed based on physical exami-
nations, vital signs (body temperature, supine blood
pressure, and supine pulse rate), resting 12-lead ECGs,
standard clinical laboratory tests (hematology, blood
biochemistry, and urinalysis), and adverse event (AE)
monitoring. Clinically signiﬁcant adverse changes in
any safety assessment, including symptoms and signs,
vital signs, ECGs, and clinical laboratory tests, were
considered AEs. The causal relationships for all AEs
were categorized by the investigator as probable,
possible, or not related.
Statistical Analysis
Plasma and urine pharmacokinetic parameters
were analyzed using SAS software, version 8.2 (studies
1 and 2), version 9.2 (study 3), or version 9.1 (studies
4 and 5) (SAS Institute, Cary, North Carolina). Safety
data were evaluated descriptively, and AEs were1033
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Clinical Therapeuticsdescribed in their entirety. All randomized subjects
who received at least 1 dose of study drug were
included in the safety analyses. Summary statistics
were calculated for all pharmacokinetic parameters by
dose or food condition. The geometric mean ratio
(GMR) (fed/fasting) of Cmax and AUC and the 90%
CI for the GMR were calculated to evaluate the effect
of food on the pharmacokinetic parameters of
mirabegron.
In studies 2, 3, 4, and 5, the GMR of the Cmax and
AUC for male versus female subjects (with 90% CIs)
were estimated to evaluate the effect of sex on
pharmacokinetic parameters.
In studies 4 and 5, the GMR of mirabegron Cmax
and AUC0–τ on the last day versus Cmax and AUC0–24
on the ﬁrst day (with 90% CIs) were estimated to assess
accumulation of mirabegron with multiple dosing.
RESULTS
Participant Disposition and Demographic
Characteristics
The disposition and demographic characteristics of
the subjects are summarized in Table I. A total of
24 healthy male subjects were enrolled in study 1;
23 subjects completed the study, and 1 subject dis-
continued the study during treatment period 2 be-
cause of AEs (headache, pyrexia, and diarrhea) under
fasting conditions. A total of 36 subjects (18 males
and 18 females) were randomized to each of the
50 and 100 mg dose groups in study 2, and 70
subjects completed the study. Two subjects
discontinued the study, one to attend the funeral of
a relative and the other because of work
commitments. A total of 12 subjects (6 males and
6 females) were enrolled in study 3, and all completed
the study. A total of 24 subjects (12 males and
12 females) were enrolled in studies 4 and 5, and all
completed both studies.
Pharmacokinetic Parameters of Mirabegron
Studies in Japanese subjects (Studies 1 and 2)
A summary of the pharmacokinetic parameters of
mirabegron in Japanese subjects under fasted or fed
conditions is given in Table II. Mean plasma
concentrations of mirabegron after single doses of
50 mg were similar between studies 1 and 2. Mean
plasma concentrations of mirabegron after single
doses of 50 and 100 mg mirabegron under fasted or
fed conditions in study 2 are shown in Figure 1. After1034 Volume 37 Number 5
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Figure 1. Mean (SD) plasma concentrations of
mirabegron after single oral adminis-
tration of mirabegron oral controlled
absorption system at 50 mg (A) and
100 mg (B) under fasted or fed con-
ditions in healthy Japanese subjects in
study 2.
H. Iitsuka et al.
May 2015administration of 50 and 100 mg doses of mirabegron,
the mean values for Cmax, AUC0–last, and AUC0–1 after
the low- and high-fat meals were lower than under
fasted conditions (study 2). After administration of
50 mg doses of mirabegron after the high-fat meal,
Cmax, AUC0–last, and AUC0–1 were approximately
53%, 32%, and 29% lower, respectively, than under
fasted conditions. After the low-fat meal, Cmax,
AUC0–last, and AUC0–1 were approximately 66%,
53%, and 51% lower, respectively, than under fasted
conditions. After administration of 100 mg mirabegron
after the high-fat meal, Cmax, AUC0–last, and AUC0–1
were approximately 49%, 29%, and 27% lower,
respectively, than under fasted conditions. After admin-
istration of 100 mg mirabegron after the low-fat meal,
Cmax, AUC0–last, and AUC0–1 were approximately1035
Clinical Therapeutics64%, 51%, and 49% lower, respectively, than under
fasted conditions (Table III). Thus, the low-fat meal
resulted in a relatively greater reduction than the high-
fat meal. Overall, there was high intersubject variability
in Cmax, AUC0–last, and AUC0–1 under all treatment
conditions (%CV of Cmax, 54%–91%; AUC0–last,
33%–49%; and AUC0–1, 32%–49%). Delays in the
mean Tmax were noted under the fed (low- and high-fat
meals) conditions compared with fasted conditions in
both the mirabegron 50 and 100 mg dose groups.
Mean t1/2 values were similar for both conditions
(50 mg: 39.9 hours under fasted, 43.4 hours after
low-fat meal, and 43.7 hours after high-fat meal;
100 mg: 36.3 hours under fasted, 37.1 hours after
low-fat meal, and 35.6 hours after high-fat meal). In
the 50 mg dose group, the percentage of unchanged
drug excreted into the urine for mirabegron was 52%
and 29% lower after the low- and high-fat meals,
respectively, compared with the fasted conditions. In
the 100 mg dose group, the mean cumulative percent-
age of unchanged drug excreted into the urine was
49% and 28% lower after the low- and high-fat meals,
respectively, compared with the fasted conditions.
Irrespective of mirabegron dose, mean renal clearance
values were similar for the 3 treatment conditions
(10.43–11.79 L/h).
Study in Taiwanese subjects (Study 3)
A summary of the pharmacokinetic parameters of
mirabegron in Taiwanese subjects under fasted or fed
conditions is given in Table IV. Mean plasma
concentrations of mirabegron after single doses of
50 mg mirabegron under fasted or fed conditions in
study 3 are shown in Figure 2. After a low-fat, low-
calorie breakfast, mean Tmax was increased by ap-
proximately 1 hour. The statistical analyses of food
effect on the pharmacokinetic parameters of mirabe-
gron are presented in Table III. Mean Cmax decreased
by approximately 29%, and mean AUC0–1 decreased
by 23%; the 90% CI of Cmax and AUC fell outside the
boundaries of 80% to 125%.
Studies in Chinese subjects (Studies 4 and 5)
A summary of the pharmacokinetic parameters of
mirabegron in Chinese subjects is given in Table V.
Mean plasma concentrations of mirabegron after
single and multiple doses of 25 and 50 mg
mirabegron in studies 4 and 5 are shown in Figure 3
and Figure 4, respectively.1036Single dose
After single-dose administration of 25 or 50 mg
mirabegron in the fasting state, the mean Cmax was
9.70 and 37.13 ng/mL, the mean AUC0–1 was 139.11
and 416.73 ng  h/mL, and the mean AUC0–24 was
64.09 and 208.49 ng  h/mL, respectively. The mean
Tmax occurred at approximately 4.0 hours after dosing
across the tested dose range. The mean t½ was
approximately 41 hours. In both studies, mean esti-
mates of CL/F decreased with increasing dose,
whereas Tmax and t½ were independent of dose across
the tested dose range.
Multiple dose
After the ﬁrst dose of 25 mg mirabegron on day 10
and of 50 mg mirabegron on day 15 of the multiple-dose
periods of studies 4 and 5, respectively, mirabegron
reached its peak plasma concentration approximately
5 hours after dosing. The mean Cmax was 4.69 and
16.06 ng/mL and the mean AUC0–24 was 33.75 and
109.97 ng  h/mL, respectively, after the ﬁrst doses of
25 and 50 mg mirabegron, respectively, in the
multiple-dose period. After multiple doses of 25 and
50 mg mirabegron, mirabegron reached a peak
plasma concentration approximately 5 hours after
doing on days 17 and 22, respectively. The mean
Cmax was 8.24 and 32.59 ng/mL and the mean AUC0–τ
was 98.96 and 320.99 ng  h/mL for the 25 and 50 mg
doses, respectively. Mean Ctrough almost reached steady
state on days 17 and 21. The GMRs of Cmax and AUC
(day 17/day 10) were 1.800 and 2.946, respectively, for
the 25 mg dose, whereas the GMRs of Cmax and AUC
(day 22/day 15) were 2.284 and 3.105, respectively, for
the 50 mg dose. Cmax and AUC of mirabegron were
higher in female subjects than in male subjects. The
GMR for female versus male subjects ranged from
1.136 to 1.412 for Cmax and from 1.374 to 1.480 for
AUC0–24 in study 4; the corresponding GMRs in study
5 ranged from 1.164 to 1.712 for Cmax and from 1.354
to 1.675 for AUC0–24 (Table VI).Tolerability
In study 1, one subject who received study drug
under fasting conditions (fed-fasting sequence group,
treatment period 2) experienced 3 serious treatment-
emergent adverse events (TEAEs) (headache, pyrexia,
and diarrhea), all of which were assessed as moderate
in severity and possibly related to the study drug.Volume 37 Number 5
Table III. Effect of food on plasma pharmacokinetic parameters of mirabegron.
Variable Study 1 (50 mg)
Study 2
Study 3 (50 mg) Study 4 (25 mg) Study 5 (50 mg)50 mg 100 mg
Study population Japanese Japanese Japanese Taiwanese Chinese Chinese
Cmax
Fasted mean 29.40 35.37 103.29 27.03 9.70 37.13
Fed
Low-fat meal
Mean — 13.40 42.86 20.23 4.69 16.06
GMR (90% CI) — 0.342
(0.263–0.443)
0.357
(0.288–0.444)
0.7111
(0.4228–1.1958)
0.519
(0.409–0.658)
0.397
(0.292–0.539)
High3
Mean 10.28 16.31 52.31 — — —
GMR4 (90% CI) 0.389
(0.275–0.552)
0.474
(0.366–0.615)
0.514
(0.414–0.639)
— — –
AUC*
Fasted mean 246.82 387.13 944.53 333.5 64.09 208.49
Fed
Low-fat meal
Mean — 195.60 506.16 249.6 33.75 109.97
GMR (90% CI) — 0.494
(0.440–0.555)
0.507
(0.459–0.560)
0.7684
(0.5865–1.0069)
0.547
(0.478–0.627)
0.489
(0.404–0.593)
High-fat meal
Mean 122.13 272.50 674.36 — — –
GMR (90% CI) 0.532
(0.441–0.643)
0.712
(0.634–0.800)
0.728
(0.659–0.805)
— — —
GMR ¼ geometric mean ratio.
*AUC0–1 in studies 1, 2, and 3 and AUC0–τ in studies 4 and 5.
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Table IV. Pharmacokinetic parameters of
mirabegron after single oral doses
of mirabegron OCAS (50 mg) in
Taiwanese subjects (study 3).*
Parameter
Fasted
(n ¼ 12)
Fed (Low-Fat Meal)
(n ¼ 12)
Cmax, ng/mL 27.03 (18.05) 20.23 (15.11)
Tmax, h 3.92 (0.79) 5.09 (0.79)
AUC0–last,
ng  h/mL
274.0 (131.8) 199.9 (97.9)
AUC0–1,
ng  h/mL
333.5 (154.5) 249.6 (116.2)
t½, h 47.53 (15.60) 49.38 (15.54)
CL/F, L/h 194.91 (128.65) 237.58 (95.50)
OCAS ¼ oral controlled absorption system.
*Data are presented as mean (SD).
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Figure 2. Mean (SD) plasma concentrations of
mirabegron after single oral adminis-
tration of mirabegron oral controlled
absorption system 50 mg under fasted
or fed conditions in healthy Taiwanese
subjects in study 3.
Clinical TherapeuticsAll these events were conﬁrmed to have resolved
during the follow-up investigation conducted within
2 days of onset. The TEAEs occurred more frequently
under fasting conditions. There was no speciﬁc pattern
of changes in laboratory test results, and no clinically
signiﬁcant ﬁndings in vital signs or ECG were noted
under fasting or fed conditions during the study.
In study 2, based on the incidence and type of AEs,
results of clinical laboratory tests, vital sign assess-
ment, and ECGs, single 50 and 100 mg doses of
mirabegron administered under fasted and fed con-
ditions (low- and high-fat meals) were well-tolerated
in healthy Japanese male and female subjects. The
mean supine pulse rate tended to increase in subjects
receiving 100 mg at 6 hours after dosing under all
treatment conditions. For the 100 mg dose group,
maximum mean changes from baseline at 6 hours
after dosing were 7.5, 5.5, and 5.4 beats/min under
fasted, low-meal, and high-fat meal conditions,
respectively.
In study 3, there were no serious AEs. Two subjects
under fed conditions (16.7%) reported Z1 TEAEs.
The reported AEs in subjects receiving mirabegron
included increased blood triglycerides, tachycardia,
and abdominal tenderness. The occurrence rate of
each event was 8.3%. All AEs in this study were mild
in severity. Two of the 3 TEAEs observed were judged
by the investigator to be possibly related to study1038drug. None of the subjects discontinued the study
because of AEs. The number of reported TEAEs under
fed conditions was higher than under fasted condi-
tions. An increase in mean pulse rate 6 hours (11.1
and 8.5 beats/min from baseline under fasted and fed
condition, respectively), 8 hours (approximately 11.9
and 7.2 beats/min from baseline under fasted and fed
condition, respectively), and 12 hours (approximately
10.8 and 9.8 beats/min from baseline under fasted and
fed condition, respectively) after administration of
mirabegron was detected.
In study 4, single and multiple oral administration
of 25 mg mirabegron was well tolerated in healthy
Chinese volunteers. One TEAE (mild hordeolum) was
reported in 1 of 24 subjects. The hordeolum was not
considered to be related to the study drug and
resolved at follow-up.
In study 5, single and multiple administration of the
50 mg mirabegron OCAS tablet was well tolerated in
healthy Chinese volunteers. A total of 10 TEAEs were
reported in 3 of the 24 subjects; drug-related TEAEs
were reported in 2 subjects. There were no TEAEs
reported inZ2 subjects. Drug-related TEAEs included
palpitations, tachycardia, abnormal hepatic function,
and decreased white blood cell count. All TEAEs were
mild in severity and resolved at follow-up. No serious
AEs or AEs leading to study discontinuation were
reported in these studies. In studies 4 and 5, no
clinically meaningful tendencies were found in meanVolume 37 Number 5
Table V. Pharmacokinetic parameters of mirabegron after single oral doses of mirabegron OCAS under fasting conditions and multiple oral doses
under fed conditions in Chinese subjects (studies 4 and 5).*
Parameter
Study 4 (25 mg) Study 5 (50 mg)
Single
(n ¼ 24)
FD (Day 10)
(n ¼ 24)
LD (Day 17)
(n ¼ 24)
Single
(n ¼ 24)
FD (Day 15)
(n ¼ 24)
LD (Day 22)
(n ¼ 24)
Cmax, ng/mL 9.70 (6.14) 4.69 (2.35) 8.24 (3.06) 37.13 (22.41) 16.06 (10.99) 32.59 (14.87)
Tmax, h 3.88 (1.26) 4.92 (1.38) 5.42 (1.14) 4.00 (1.25) 5.21 (0.88) 5.42 (1.56)
AUC0–1, ng  h/mL 139.11 (57.95) — — 416.73 (138.52) — —
AUC,† ng  h/mL 64.09 (29.80) 33.75 (11.16) 98.96 (28.72) 208.49 (79.18) 109.97 (53.70) 320.99 (113.66)
t½, h 40.39 (8.75) — 48.30 (9.04) 41.30 (8.27) — 45.89 (11.00)
CL/F, L/h 207.61 (79.60) — 282.51 (116.28) 134.14 (46.11) — 192.69 (132.47)
FD ¼ ﬁrst day; LD ¼ last day; OCAS ¼ oral controlled absorption system.
*Data are presented as mean (SD).
†AUC0–24 for single dose and AUC0–τ for multiple dose.
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Table VI. Effect of sex on the pharmacokinetic parameters of mirabegron after single (fasted) or multiple (fed) oral doses of mirabegron OCAS.
Variable
Study 2 (Single Dose) Study 3
Study 4 Study 5
Single dose FD (Day 10) LD (Day 17) Single dose FD (Day 15) LD (Day 22)
50 mg 100 mg (Single Dose of 50 mg) 25 mg 25 mg 25 mg 50 mg 50 mg 50 mg
Study population Japanese Japanese Taiwanese Chinese Chinese Chinese Chinese Chinese Chinese
Cmax
Mean of female 42.51 117.78 37.50 11.36 5.05 9.34 37.32 21.00 37.23
Mean of male 28.63 89.60 16.56 8.05 4.33 7.14 36.93 11.11 27.95
GMR (90% CI)2 1.276
(0.877–1.856)
1.452
(1.053–2.002)
2.211
(1.149–4.254)
1.276
(0.828–1.965)
1.136
(0.811–1.591)
1.412
(1.048–1.904)
1.164
(0.764–1.772)
1.712
(0.991–2.957)
1.521
(1.019–2.271)
AUC0–1
Mean of female 446.32 1156.92 429.5 167.71 — — 474.45 — —
Mean of male 331.22 743.94 237.4 110.50 — — 359.02 — —
GMR (90% CI)2 1.337
(1.078–1.658)
1.600
(1.334–1.918)
1.869
(1.174–2.974)
1.432
(1.121–1.830)
— — 1.347
(1.081–1.680)
— —
AUCa
Mean of female — — — 78.81 38.95 114.48 236.76 135.80 388.09
Mean of male — — — 49.38 28.56 83.45 180.22 84.14 253.88
GMR (90% CI)2 — — — 1.480
(1.124–1.949)
1.374
(1.106–1.705)
1.423
(1.156–1.751)
1.354
(1.053–1.741)
1.615
(1.091–2.390)
1.675
(1.275–2.199)
FD ¼ ﬁrst day; GMR ¼ geometric mean ratio; LD ¼ last day; OCAS ¼ oral controlled absorption system.
2Female/Male
aAUC0–24 for single dose and AUC0–τ for multiple dose.
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H. Iitsuka et al.After administration of mirabegron in Japanese and
Taiwanese subjects, Cmax and AUC0–1 under fed
conditions were lower than under fasted condition,
which indicated that there is a decrease in absorption
when the drug is taken with food (Cmax and AUC0–1
were approximately 30% to 65% lower than under
fasted conditions). In studies 4 and 5, Cmax and
AUC0–24 of mirabegron on the ﬁrst day of multiple
dosing under fed conditions were lower than those
after a single dose under fasted conditions (mean Cmax
of 9.70 and 4.69 ng/mL and mean AUC0–24 of 64.09
and 33.75 ng  h/mL under fasted and fed conditions,
respectively, for the 25 mg dose; mean Cmax of 37.13
and 16.06 ng/mL and mean AUC0–24 of 208.49 and
109.97 ng  h/mL under fasted and fed conditions,
respectively, for the 50 mg dose). Although the food
effect on the pharmacokinetic parameters of mirabe-
gron in Taiwanese subjects (in whom Cmax and
AUC0–1 were 29% and 23% lower than under fasted
conditions, respectively) was smaller than in Japanese
subjects (in whom Cmax and AUC0–1 were 66% and
51% lower than under fasted conditions, respec-
tively), the trend was similar for both Japanese and
Taiwanese subjects. In study 2 in Japanese subjects, a
greater reduction in mirabegron Cmax and AUC0–1
was observed after a low-fat meal than after a high-fat
meal (50 mg: after the high-fat meal doses of mirabe-
gron, Cmax and AUC0–1 were approximately 53%
and 29% lower, and after the low-fat meal doses,
Cmax and AUC0–1 were approximately 66% and
51% lower than under fasted condition, respectively;
100 mg: after the high-fat meal doses of mirabegron,
Cmax and AUC0–1 were approximately 49% and
27% lower, and after the low-fat meal, Cmax and
AUC0–1 were approximately 64% and 49% lower
than under fasted condition, respectively), as observed
in Western subjects.8 According to the Biopharma-
ceutics Classiﬁcation System, mirabegron may be con-
sidered class 3 with high solubility and low
permeability.12 Therefore, transporters may be
important for mirabegron absorption. Mirabegron is
a substrate of P-glycoprotein.12 A postulated mecha-
nism that may contribute to the observed food effect
with mirabegron is unclear; however, it may in part be
attributable to drug-transporter and food-transporter
interactions.13 Food intake may lead to a prolonged
gastric residence time. In addition, luminal concen-
trations of mirabegron are likely to be lower and
insufﬁcient to saturate P-glycoprotein transporters,May 2015resulting in reduced bioavailability and plasma ex-
posure compared with those in the fasted state. The
differences in composition of the high-fat and low-fat
meals may also differentially affect intestinal transport
of mirabegron. Lipids, in particular monoglycerides,
contained in a high-fat meal or its digests have been
reported to inhibit P-glycoprotein transport.14,15 Mir-
abegron has also previously been reported to have
been adsorbed to food components, especially by
components of low-fat meals.8
In studies in healthy Chinese subjects, mirabegron
Cmax was reached approximately 4 hours after oral
administration of a single dose and approximately 5
hours after multiple-dose administration. Steady-state
conditions were reached on days 7 to 8 after once-
daily administration with mirabegron, and accumu-
lation of mirabegron was approximately 2- to 3-fold.
These ﬁndings are in accordance with previously
published single- and multiple-dose studies in healthy
Japanese male subjects.6 Although the 25 and 50 mg
dose studies were separately conducted, mirabegron
Cmax and AUC0–1 increased more than propor-
tionally with dose in Chinese subjects. In addition,
after administration of mirabegron in Japanese,
Taiwanese, and Chinese subjects, mean values for
Cmax and AUC in female subjects were higher than
those in male subjects (Table VI). There were no
apparent differences in the magnitude of the sex
difference among the 3 populations. The mean
weight of male subjects (61.9 to 70.2 kg) was
higher than that of female subjects (53.0 to 56.6 kg)
(Table I). The previous studies in Europe also found
that female subjects generally had 44% greater
mirabegron Cmax and 38% greater AUC than males,
which was partly related to sex differences in weight.5
Weight-normalized values for Cmax and AUC were
23% and 18% higher, respectively, in females than in
males. Furthermore, absolute bioavailability of mir-
abegron in females tends to be larger than in males
(approximately 12.7%). Sex differences in exposure
could be explained by weight and absolute
bioavailability.4
The mean Cmax after a 50 mg dose of mirabegron
under fasted conditions in male Japanese (study 2),
Taiwanese (study 3), and Chinese (study 5) subjects was
35.37, 27.03, and 37.13 ng/mL, respectively. The mean
AUC0–1 was 387.13, 333.5, and 416.73 ng  h/mL,
respectively. Therefore, the pharmacokinetic proﬁles of
mirabegron are similar in healthy Japanese, Taiwanese,1041
Clinical Therapeuticsand Chinese subjects. These ﬁndings are reasonable in
view of mirabegron’s drug disposition in which the
elimination of mirabegron is likely to be through
both biliary and renal excretion of unchanged drug
and metabolism.7 Renal clearance accounts for
approximately 25% of total clearance from plasma.4
The rest of its elimination occurs through metabolism
and excretion of unchanged drug in feces. Indeed,
metabolism is one of the major elimination pathways
of mirabegron.
The results of in vitro and in vivo studies suggest
involvement of butyrylcholinesterase, UDP-glucurono-
syltransferases (UGT), and possibly alcohol dehydro-
genase in the metabolism of mirabegron.7,16 In
addition, cytochrome 450 (CYP) 3A4 is the primary
isoenzyme responsible for the hepatic oxidative meta-
bolism of mirabegron in vitro, with a minor role of
CYP2D6.16 Mirabegron is cleared by multiple
metabolic enzymes with no single enzyme dominant.
From the results of the clinical studies, mirabegron
is not considered a sensitive substrate of CYP3A
in vivo because ketoconazole increased mirabegron
exposure by o2-fold. In addition, the effect of the
CYP2D6 phenotype on mirabegron exposure is small
and likely of limited clinical importance.17 There is a
report that subjects native to Japan, China, and Korea
can be expected to have similar metabolic ratios for
drugs primarily cleared by major CYPs, including
CYP3A4 and CYP2D6.18 In addition, it seems that
ethnic differences in CYP3A4 polymorphisms, parti-
cularly in Asians, are very rare and do not appear to
fully explain the large individual variation in CYP3A4
activity.19 Therefore, CYP polymorphism may not
play a role in the pharmacokinetic variability of
mirabegron in an East Asian population.
Both human butyrylcholinesterase and UGTs are
metabolic enzymes for mirabegron. Butyrylcholines-
terase is coded by the BCHE gene included some
mutations lead to catalytic disturbance.20,21 UGTs are
well known to have 4 subfamilies: UGT1, UGT2,
UGT3, and UGT8.22 It is unclear whether there are
ethnic differences in these enzymes among Asian
populations. Because mirabegron is cleared by multi-
ple pathways, differences in enzymatic metabolism
due to ethnicity might also be expected to have a small
effect on the pharmacokinetic parameters of mira-
begron in East Asian populations.
On the other hand, several aspects of these studies,
such as extrinsic ethnic factors, have to be considered1042when comparing their results. First, they were con-
ducted in different countries, at different centers, and
at different times, although evaluation of food effect
on the pharmacokinetic parameters was performed
with similar food content. The pharmacokinetic pa-
rameters of mirabegron are similar among Japanese,
Taiwanese, and Chinese subjects. This information is
important for use of mirabegron in East Asian
countries.
To compare the Western5 and East Asian
populations, the subject demographic characteristics
were compared. The mean ages of the Western (27.6
to 30.3 years) and East Asian (23.4 to 33.3 years) male
and female subjects were similar (Table I). The mean
weight of young Western male and female subjects
(68.9 to 77.1 kg and 58.8 to 64.6 kg, respectively) was
higher than that of young East Asian male and female
subjects (61.9 to 70.2 kg and 53.0 to 56.6 kg,
respectively) (Table I). A comparison of mirabegron
exposure in East Asian and Western healthy subjects
revealed that the mean AUC values for mirabegron in
East Asian male and female subjects after single 50 mg
doses were higher than those observed in Western male
and female individuals as reported previously.5 Weight
might be one of the factors that affect these differences
in exposure. In a previous report of Japanese single-
and multiple-dose studies, the differences in mirabe-
gron exposure were smaller when values were normal-
ized for weight between Japanese and Western
subjects.6 These ﬁndings are in accordance with
previously published pharmacokinetic proﬁles in
healthy Western subjects.5,6,8
The effects of food and sex on bioavailability of
mirabegron were not clinically relevant. Mirabegon is
used without dose adjustment based on sex and food
consumption in clinical practice.23,24 Mirabegron was
well tolerated in healthy Japanese, Taiwanese, and
Chinese subjects.
CONCLUSIONS
Our studies indicate higher exposure levels of mirabegron
in female compared with male Japanese, Taiwanese, and
Chinese subjects as found earlier in Western subjects.
Furthermore, the effects of food on the pharmacokinetic
parameters of mirabegron appeared to be similar among
the 3 populations tested in our studies. A greater
reduction in mirabegron Cmax and AUC0–1 was observed
after a low-fat meal compared with a high-fat meal in
Japanese subjects. The overall ﬁndings suggest that thereVolume 37 Number 5
H. Iitsuka et al.are no signiﬁcant pharmacokinetic parameter differences
among Japanese, Taiwanese, and Chinese populations.
Mirabegron was well tolerated in healthy Japanese,
Taiwanese, and Chinese subjects.
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